Analyze HCM

ShareShare on WhatsApp Share on Facebook Share on X

Equity Research · Deep diveIT-2026-HCM · 2026-07-30

HUTCHMED (China) Limited (HCM)

HealthcareDrug Manufacturers - Specialty & GenericNasdaqGSMarket cap $1.96B

$11.39

+1.70%

Analyst-style PDF, emailed within minutes

52/100

Mixed picture

Automated weighted score · not a recommendation

Price source: Yahoo · live price · as of 23:00 · Data: Yahoo · SEC EDGAR · FINRA · Wikidata

About the company

Market cap

$1.96B

P/E

4.23

Beta

0.43

Employees

1.80K

Sector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: NasdaqGSCountry: Hong Kong Website

What the company does

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Day range

$11.30$11.60

52-week range

$9.77$19.50

Price alert on HCM

Get an in-app and mobile alert every time HCM crosses a price you set.

Loading short data…

HCM · Chart

Loading chart…

SMA20 SMA50 SMA200

Charts by TradingView

Support & resistance

Key trading levels, by timeframe

Day

Swing

Computing levels…

The technical signal compass

Sign up free and build your own trading bot with full backtesting. Live bots, real-time alerts and the bot gallery — with a Pro subscription.

Free sign-up

HUTCHMED (China) Limited (HCM) is trading around $11.39 (+1.70% on the last session). Its 52-week range runs from $9.77 to $19.50. Technically: 3 buy signals, 5 sell and 4 neutral. It belongs to the Healthcare sector (Drug Manufacturers - Specialty & Generic), with a P/E of 4.2 and a 2B$ market cap. Data sourced from Yahoo · live price as of 23:00. This is data analysis only, not advice or a recommendation.

HCM stock FAQ

What is HCM's current price?

HCM is trading around $11.39 (+1.70%), as of 23:00 per Yahoo · live price.

What is HCM's 52-week price range?

Over the last 52 weeks HCM ranged between a $9.77 low and a $19.50 high.

Which sector does HCM belong to?

HCM belongs to the Healthcare sector, Drug Manufacturers - Specialty & Generic industry.

Disclosure & disclaimer: All information, scores, signals and trade plans on this site are produced by an automated algorithmic system and are based on technical and quantitative data only. They do not constitute investment advice, investment marketing or a recommendation to act, and are not a substitute for personal advice from a licensed professional that accounts for your needs and circumstances. We are not investment advisors. Trading securities involves substantial risk, up to the loss of your entire investment; every decision and action is your sole responsibility. i-trade and its operators bear no liability for any direct or indirect damage arising from reliance on this information.

0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ %€ ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇% ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 01 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 #$ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 €↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1

Building the strategy

HCM stock FAQ

What is HCM's current price?

HCM is trading around $11.39 (+1.70%), as of 23:00 per Yahoo · live price.

What is HCM's 52-week price range?

Over the last 52 weeks HCM ranged between a $9.77 low and a $19.50 high.

Which sector does HCM belong to?

HCM belongs to the Healthcare sector, Drug Manufacturers - Specialty & Generic industry.

Analyze HCM

HUTCHMED (China) Limited (HCM)

About the company

HCM · Chart

Support & resistance

The technical signal compass

HCM stock FAQ

HUTCHMED (China) Limited (HCM)

About the company

HCM · Chart

Support & resistance

The technical signal compass

HCM stock FAQ

Income statement analysis

Institutional & insider data

Full analyst coverage